Score Overview
Explore the 2021 public Archive ranking β
Where Eterna Therapeutics Inc has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- ERNA
2020: 94.8% Β· 2021: 72.0% Β· free through 2021 Β· longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-11-17 | $ 1.63 | β |
1 Year2025-11-17 | $ 37.75 | -95.68% |
5 Years2021-11-17 | $ 56.7K | -100.00% |
10 Years2016-11-17 | $ 109.8K | -100.00% |
20 Years2006-11-17 | $ 18.6K | -99.99% |
30 Years1996-11-15 | $ 56.25K | -100.00% |
All Time1992-10-19 | $ 56.25K | -100.00% |
| Period | Last Price2026-11-17 | 1 Year2025-11-17 | 5 Years2021-11-17 | 10 Years2016-11-17 | 20 Years2006-11-17 | 30 Years1996-11-15 | All Time1992-10-19 |
|---|---|---|---|---|---|---|---|
| Price | $ 1.63 | $ 37.75 | $ 56.7K | $ 109.8K | $ 18.6K | $ 56.25K | $ 56.25K |
| Return | β | -95.68% | -100.00% | -100.00% | -99.99% | -100.00% | -100.00% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 0.00 | -$ 13M | $ 5M |
| 2025 | $ 0.00 | -$ 14M | $ 1M |
| 2024 | $ 582K | -$ 44M | $ 1M |
| 2023 | $ 68K | -$ 21M | $ 7M |
| 2022 | $ 0.00 | -$ 24M | $ 11M |
| 2021 | $ 0.00 | -$ 122M | $ 16M |
| 2020 | $ 5M | $ 11M | $ 1M |
| 2019 | $ 19M | -$ 2M | $ 3M |
| 2018 | $ 23M | -$ 259K | $ 2M |
| 2017 | $ 21M | -$ 1M | $ 3M |
| 2016 | $ 22M | -$ 2M | $ 5M |
| 2015 | $ 24M | -$ 7M | $ 3M |
| 2014 | $ 26M | -$ 5M | $ 7M |
| 2013 | $ 23M | -$ 1M | $ 5M |
| 2012 | $ 24M | -$ 995K | $ 2M |
| 2011 | $ 23M | -$ 3M | $ 1M |
| 2010 | $ 25M | -$ 400K | $ 3M |
| 2009 | $ 25M | -$ 1M | $ 3M |
| 2008 | $ 3M | ||
| 2007 | $ 10M | ||
| 2006 | $ 32M | -$ 4M |

Eterna Therapeutics Inc fundamental performance
Between 2015 and 2025, revenue declined from $ 24M to $ 0.00 and net income went from -$ 7M to -$ 14M. Revenue increased in 3 of those 10 years; net income in 7.
Across Eterna Therapeutics Inc's full reported history, from 2006 to 2025, revenue declined from $ 32M to $ 0.00 and net income went from -$ 4M to -$ 14M. Revenue increased in 29% of the years measured; net income in 59%.
Eterna Therapeutics Inc currently holds a 20-year HDB Score of 2.3 out of 10. How the HDB Score is calculated.
Membership
Continue ERNAβs history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,187 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio




